thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
Follow US
© thenewsfacts : All Rights Reserved.

Home » World’s 1st intra nasal vaccine iNCOVACC by Bharat Biotech approved for emergency use

COVID Vaccines

World’s 1st intra nasal vaccine iNCOVACC by Bharat Biotech approved for emergency use

TheNewsFacts
Last updated: September 6, 2022 7:17 pm
TheNewsFacts
Share
World’s 1st intra nasal vaccine iNCOVACC by Bharat Biotech approved for emergency use
SHARE

Bharat Biotech’s intra nasal vaccine iNCOVACC (BBV154), has received approval under Restricted Use in Emergency Situation for ages 18 and above in India. This is World’s First Intranasal Vaccines to receive approvals for Primary 2 dose schedule .

Highlights of Bharat Biotech Intra Nasal Vaccine – iNCOVACC

Intra Nasal Vaccine
Bharat Biotech’s Intra Nasal Vaccine iNCOVACC gets emergency use approval in India
  • iNCOVACC receives approval under Restricted Use in Emergency Situations for ages 18 and above.
  • Bharat Biotech is a global leader in intranasal vaccine technologies.
  • Phase III trials were conducted for safety, immunogenicity in ~3100 subjects, in 14 trial sites across India.
  • Heterologous booster dose studies were conducted for safety and immunogenicity in ~875 subjects, with BBV154 intranasal vaccine administered post 2 doses of the two commonly administered covid-19 vaccines. The trials were conducted in 9 trial sites across India.

iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results.

iNCOVACC has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost effective in low- and middle-income countries.

iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy. Product development related to preclinical safety evaluation, large scale manufacturing scale up, formulation and delivery device development, including human clinical trials were conducted by Bharat Biotech.

The Product development and clinical trials were funded in part by the Government of India through the Department of Biotechnology’s, COVID Suraksha program.

Clinical trials were conducted to evaluate iNCOVACC as a primary dose schedule, as heterologous booster dose for subjects who have previously received 2 doses of the two commonly administered covid vaccines in India.

Immunogenicity was evaluated through serum neutralizing antibodies by PRNT assays and serum IgG’s through ELISA’s. To evaluate vaccines taken through the intranasal route, IgA’s were evaluated by ELISA in serum and saliva. Evaluation was also carried out for ability iNCOVACC to elicit long term memory T and B cell responses against the ancestral and omicron variants.

Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech, said, “We are proud to announce the approval of iNCOVACC, a global game changer in Intra Nasal vaccines technology and delivery systems. Despite the lack of demand for COVID-19 vaccines, we continued product development in intra nasal vaccines to ensure that we are well prepared with platform technologies for future infectious diseases. We thank the Ministry of Health, the CDSCO, Dept of Biotechnology Govt of India, and Washington University St. Louis for their support and guidance. iNCOVACC has been designed for efficient distribution and easy administration.”

iNCOVACC was evaluated to determine its impact on safety. The reactogenic events and adverse events that were documented during the trial were highly comparable to published data from other covid-19 vaccines. Product development data will be submitted to peer reviewed journals and will be made available in the public domain.

iNCOVACC has the double benefit of enabling faster development of variant specific vaccines and easy nasal delivery that enables mass immunization to protect from emerging variants of concern. It promises to become an important tool in mass vaccinations during pandemics and endemics. With the receipt of approval today, the product will be launched and available for use in due course of time.

iNCOVACC is stable at 2-8°C for easy storage and distribution. Bharat Biotech has established large manufacturing capabilities at multiple sites across India, including Gujarat, Karnataka, Maharashtra and Telangana with operations pan India.

TAGGED: Bharat Biotech Nasal Vaccine, iNCOVACC, Intra Nasal Vaccine, Nasal Covid 19 Vaccine
Share This Article
Twitter Email Copy Link Print
Previous Article Suresh Raina bids adieu to all formats of cricket, India loses a big talent Suresh Raina bids adieu to all formats of cricket, India loses a big talent
Next Article Bengaluru Floods: Big Indian cities crumble under nature's wrath Bengaluru Floods: Big Indian cities crumble under nature’s wrath

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
TwitterFollow
InstagramFollow

Popular Posts

Twitter faces fresh labour lawsuit for more than 3000 unlawful Jobcuts

Twitter, a widely popular social media platform, is currently facing a legal challenge as allegations…

By TheNewsFacts

Rafael Nadal Bags 3rd Big Title of 2022, Wins Acapulco ATP 500 Cup

Rafa Nadal won his fourth title in Acapulco this weekend ( Saturday), continuing his good…

By TheNewsFacts

Reuters Danish Siddiqui killing in Kandahar Shocks the world

Reuters Indian photojournalist Danish Siddiqui killed in Kandahar in Afghanistan, has shocked the nation and…

By TheNewsFacts

You Might Also Like

Covaxin BHU Study
COVID VaccinesLatest News

Covaxin BHU Study: BB Points Flaws in Data Points, Backs Strong Safety Track Record

By NewsFacts Bureau
COVAXIN
COVID Vaccines

COVAXIN production to be demand-driven, says Bharat Biotech

By TheNewsFacts
iNCOVACC: Bharat Biotech Reveals World's 1st Nasal COVID Vaccine Price
COVID Vaccines

iNCOVACC: Bharat Biotech Reveals World’s 1st Nasal COVID Vaccine Price

By TheNewsFacts
Bharat Biotech iNCOVACC Vaccine priced ₹800 in CoWIN, ₹325 for the Govt Supplies, Rollout in January 2023
COVID Vaccines

Bharat Biotech iNCOVACC Vaccine priced ₹800 in CoWIN, ₹325 for the Govt Supplies, Rollout in January 2023

By TheNewsFacts
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?